Camlin Fine Sciences Q2 & H1 FY'26 Earnings Call Transcript
Camlin Fine Sciences' Q2 FY26 earnings call reveals ₹460Cr revenue, 8.6% growth, and strategic moves including a French acquisition. Volumes increased, but tariffs impact Vanillin realization. Optimistic outlook for blends and Vanillin sales.
The announcement provides insights into the company's financial performance and future strategies, which is relevant for investors.
The earnings call discussed positive revenue growth and strategic acquisitions, indicating a positive outlook for the company.
* Camlin Fine Sciences held a conference call on November 10, 2025, regarding the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025. * Revenue for the quarter was ₹460 crore, an 8.6% increase over the last quarter, fueled by the trades and blends vertical. * Volumes in the Straights business increased by around 40%. * Blends business grew by around 8% with margins improving by around 2% compared to the last quarter. * Vanillin business volume increased almost by 35%, but realizations were under pressure due to tariffs. * EBITDA for the quarter was around ₹33 crore at 7.27%. * The company is on the verge of swapping shares with a new acquisition in France, expected to become a subsidiary sometime in this quarter. * De-stocking in the US is expected to be completed by Q4 of this year, and in Europe by Q1 of FY '27. * The company expects Vanillin volumes of 2,500 tons this year and aims for 18%-20% growth in blends. * The company is on track for about ₹2,000-₹2,100 crore in sales. * The company expects to achieve about 4,000 tons in Vanillin sales next year and a 20% growth in the Blends business. * Nirmal Momaya mentioned that the company is looking at about 4,000 tons in Vanillin sales in the next year and the Blends business is expected to grow by 20%.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.